Crossmark

The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD

Crossref DOI link: https://doi.org/10.1007/s12325-022-02229-8

Published Online: 2022-07-03

Published Print: 2022-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kolb, Martin https://orcid.org/0000-0003-3837-1467
Orfanos, Stylianos E. https://orcid.org/0000-0001-6186-6199
Lambers, Chris https://orcid.org/0000-0001-5866-5417
Flaherty, Kevin https://orcid.org/0000-0001-7686-0291
Masters, Alison https://orcid.org/0000-0002-4572-4323
Lancaster, Lisa https://orcid.org/0000-0001-8465-7357
Silverstein, Adam https://orcid.org/0000-0002-8366-7294
Nathan, Steven D. https://orcid.org/0000-0002-6270-1617
Funding

Funding for this research was provided by:

United Therapeutics Corporation
License Information

Text and Data Mining valid from 2022-07-03

Version of Record valid from 2022-07-03
More Information

Article History

Received: 2 May 2022

Accepted: 15 June 2022

First Online: 3 July 2022